(Q37930978)

25 August 2017

1 reference

title

Management of psoriatic arthritis from the view of the dermatologist (English)

1 reference

25 August 2017

1 reference

Caroline A Chang

1

1 reference

25 August 2017

Alice B Gottlieb

series ordinal

2

1 reference

25 August 2017

Paul F Lizzul

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

13 September 2011

1 reference

Nature Reviews Rheumatology

25 August 2017

published in

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

588-598

1 reference

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Epidemiology of psoriatic arthritis in the population of the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Psoriatic arthritis and psoriasis: need for a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Follicular mucinosis: clinical, histologic, and molecular remission with minocycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Development of a preliminary composite disease activity index in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Which chronic conditions are associated with better or poorer quality of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Psychologic factors in psoriasis: consequences, mechanisms, and interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Treatment recommendations for psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

How to prevent glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

A randomized trial of etanercept as monotherapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Psoriatic arthritis sine psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Mortality in Psoriatic Arthritis – A Single-center Study from the UK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Suicidal ideation in psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Nonsteroidal anti-inflammatory drug gastropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Efficacy of etanercept in psoriatic patients previously treated with infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Autoantibody production in patients treated with anti-TNF-alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Etanercept as monotherapy in patients with psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.125

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

31 March 2020

1 reference

12 December 2020

Outcome measures in psoriatic arthritis

1 reference

12 December 2020

Consensus on a core set of domains for psoriatic arthritis

1 reference

12 December 2020

The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress

1 reference

12 December 2020

Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines

1 reference

12 December 2020

METHOTREXATE THERAPY IN PSORIATIC ARTHRITIS; DOUBLE-BLIND STUDY ON 21 PATIENTS

1 reference

12 December 2020

The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.

1 reference

12 December 2020

Comparison of disability and quality of life in rheumatoid and psoriatic arthritis

1 reference

12 December 2020

The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

1 reference

12 December 2020

Mortality in psoriatic arthritis.

1 reference

12 December 2020

A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis

1 reference

12 December 2020

Clinical and genetic aspects of psoriatic arthritis "sine psoriasis"

1 reference

12 December 2020

Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2011.125

1 reference

25 August 2017

1 reference